Canaccord raised the firm’s price target on Rocket Pharmaceuticals to $50 from $47 and keeps a Buy rating on the shares. The firm said its 3Q earnings report was incrementally positive with pipeline updates largely on track and the announcement of the company’s successful alignment with the FDA on a pivotal Ph2 trial design for RP-L301 in PKD.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RCKT:
- Rocket Pharmaceuticals reports Q3 EPS (75c), consensus (81c)
- RCKT Earnings this Week: How Will it Perform?
- Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
- Rocket Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
- Rocket says FDA accepts BLA with priority review for RP-L201 to treat LAD-I
